Mycosis fungoides: disease evolution of the "lion queen" revisited

被引:0
作者
Quaglino, P. [1 ]
Pimpinelli, N. [2 ]
Berti, E. [3 ]
Calzavara-Pinton, P. [4 ]
Lombardo, G. A. [5 ]
Rupoli, S. [6 ]
Alaibac, M. [7 ]
Arcaini, L. [8 ]
Bagnato, S. [9 ]
Baldo, A. [10 ]
Bottoni, U. [11 ]
Carbone, A. [12 ]
Cestari, R. [13 ]
Clerico, R. [14 ]
De Renzo, A. [15 ]
Fava, P. [1 ]
Fierro, M. T. [1 ]
Filotico, R. [16 ]
Fimiani, M. [17 ]
Frontani, M.
Girgenti, V. [18 ]
Goteri, G. [19 ]
Leali, C. [4 ]
Mamusa, A. M. [20 ]
Mariotti, G. [2 ]
Mastrandrea, V. [21 ]
Pellegrini, C. [22 ]
Pennese, E. [23 ]
Pileri, A. [24 ]
Savoia, P. [1 ]
Stelitano, C. [25 ]
Titli, S. [1 ]
Virgili, A. [26 ]
Zichichi, L. [27 ]
Zinzani, P. L. [22 ]
Bernengo, M. G. [1 ]
机构
[1] Univ Turin, Dermatol Clin, Dept Biomed Sci & Human Oncol, Turin, Italy
[2] Univ Florence, Dept Crit Care Med, Dermatol Sect, Florence, Italy
[3] Univ Milano Bicocca, Dermatol Clin, Milan, Italy
[4] Univ Brescia, Inst Dermatol, Brescia, Italy
[5] IRCCS, IDI, Div Dermatol 53, Rome, Italy
[6] Univ Ancona, Inst Hematol, I-60128 Ancona, Italy
[7] Univ Padua, Unit Dermatol, I-35100 Padua, Italy
[8] Univ Pavia, Div Hematol, Dept Oncohematol, Sch Med,Fdn IRCCS Policlin S Matteo, I-27100 Pavia, Italy
[9] Hosp Catania, Hematol & Oncol Unit, Catania, Italy
[10] Univ Naples Federico II, Dermatol Clin, Naples, Italy
[11] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Dermatol Unit, Catanzaro, Italy
[12] Sacro Cuore Catholic Univ, Dept Dermatol, Rome, Italy
[13] La Spezia Hosp, Unit Dermatol, Rome, Italy
[14] Univ Roma La Sapienza, Dept Dermatol, Rome, Italy
[15] Univ Naples Federico II, Div Hematol, Naples, Italy
[16] Hosp APerrino, Dermatol Unit, Brindisi, Italy
[17] Univ Siena, Inst Dermatol, I-53100 Siena, Italy
[18] Univ Milan, IRCCS Fdn Ca Granda, Dept Anesthesiol Intens Therapy & Dermatol Sci, Unit Dermatol, Milan, Italy
[19] Univ Ancona, Inst Pathol, Ancona, Italy
[20] Oncol Hosp A Businco, Hematol & Stem Cell Transplant Unit, Cagliari, Italy
[21] Univ Bari, Dermatol Clin 2, Bari, Italy
[22] Univ Bologna, St Orsola Malpighi Policlin, Inst Hematol & Med Oncol L&A Seragnoli, Bologna, Italy
[23] Hosp Vito Fazzi, Hematol & Stem Cell Transplant Unit, Lecce, Italy
[24] Univ Bologna, Div Dermatol, Dept Internal Med Geriatr & Nephrol, Bologna, Italy
[25] Hosp Reggio Calabria, Hematol Unit, Reggio Di Calabria, Italy
[26] Univ Ferrara, Dept Clin & Expt Med, Dermatol Sect, I-44100 Ferrara, Italy
[27] Hosp Trapani, Dermatol Unit, Trapani, Italy
来源
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA | 2012年 / 147卷 / 06期
关键词
Mycosis fungoides; Lymphoma; T-cell; cutaneous Prognosis; Dermatitis; exfoliative; T-CELL LYMPHOMA; SEZARY-SYNDROME; PROGNOSTIC-FACTORS; INTERNATIONAL-SOCIETY; EUROPEAN-ORGANIZATION; CUTANEOUS-LYMPHOMAS; UNITED-STATES; EORTC CLASSIFICATION; TASK-FORCE; SURVIVAL;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Mycosis fungoides (MF), which represents the most common subtype of primary cutaneous T-cell lymphoma (CTCL), is an epidermotropic lymphoma included as an indolent form in the recent WHO/EORTC classification. From a clinical point of view, the classic disease progression usually is slow and takes over years or even decades, and characterized by the evolution from patches to more infiltrated plaques and eventually to tumours or erythroderma. However, the analysis of the MF disease course has been greatly impaired by the rarity of the disease, thus data about the time course of disease progression and pattern of relapse during time are not well known. In this review, a summary of published data on MF large patients cohorts will be presented, together with the results obtained by a retrospective analysis of clinical features and follow-up data of 1,422 MF patients diagnosed and followed-up from 1975 to 2010 in 27 Italian Centres (Italian Study Group for Cutaneous Lymphoma). From a clinical perspective, the amount of data support the relevance of a stage-tailored, differentiated follow-up strategy, in as much as the TNMB staging appears not only to be associated with different progression rates, but also shows as a new finding a relationship with different patterns of disease progression. From a biological point of view, there is the need to understand the molecular basis of the different clinical pathways of disease progression, to be able to potentially identify at an earlier phase of disease evolution, the patients who are more likely to develop erythroderma or tumour-stage progression. In conclusion, if ME is indeed a true "lion queen", as dermatologists we need to be expert and wise tamers to keep it under control.
引用
收藏
页码:523 / 531
页数:9
相关论文
共 35 条
  • [1] Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sezary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal
    Agar, Nita Sally
    Wedgeworth, Emma
    Crichton, Siobhan
    Mitchell, Tracey J.
    Cox, Michael
    Ferreira, Silvia
    Robson, Alistair
    Calonje, Eduardo
    Stefanato, Catherine M.
    Wain, Elizabeth Mary
    Wilkins, Bridget
    Fields, Paul A.
    Dean, Alan
    Webb, Katherine
    Scarisbrick, Julia
    Morris, Stephen
    Whittaker, Sean J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) : 4730 - 4739
  • [2] Mycosis fungoides and Sezary syndrome:: therapeutic approach and outcome in 113 patients
    Anadolu, RY
    Birol, A
    Sanli, H
    Erdem, C
    Türsen, Ü
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2005, 44 (07) : 559 - 565
  • [3] Prognostic factors in Sezary syndrome: A multivariate analysis of clinical, haematological and immunological features
    Bernengo, MG
    Quaglino, P
    Novelli, M
    Cappello, N
    Doveil, GC
    Lisa, E
    De Matteis, A
    Fierro, MT
    Appino, A
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (08) : 857 - 863
  • [4] Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases
    Bradford, Porcia T.
    Devesa, Susan S.
    Anderson, William F.
    Toro, Jorge R.
    [J]. BLOOD, 2009, 113 (21) : 5064 - 5073
  • [5] BUNN PA, 1979, CANCER TREAT REP, V63, P725
  • [6] Incidence of cutaneous T-Cell lymphoma in the United States, 1973-2002
    Criscione, Vincent D.
    Weinstock, Martin A.
    [J]. ARCHIVES OF DERMATOLOGY, 2007, 143 (07) : 854 - 859
  • [7] Prognostic factor analysis in mycosis fungoides/Sezary syndrome
    Diamandidou, E
    Colome, M
    Fayad, L
    Duvic, M
    Kurzrock, R
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (06) : 914 - 924
  • [8] Transformation of mycosis fungoides/Sezary syndrome: Clinical characteristics and prognosis
    Diamandidou, E
    Colome-Grimmer, M
    Fayad, L
    Duvic, M
    Kurzrock, R
    [J]. BLOOD, 1998, 92 (04) : 1150 - 1159
  • [9] Primary Sezary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism
    Diwan, AH
    Prieto, VG
    Herling, M
    Duvic, M
    Jones, D
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (04) : 510 - 515
  • [10] Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what?
    Dummer, R.
    Assaf, C.
    Bagot, M.
    Gniadecki, R.
    Hauschild, A.
    Knobler, R.
    Ranki, A.
    Stadler, R.
    Whittaker, S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (16) : 2321 - 2329